KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Gross Profit (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Gross Profit data on record, last reported at $16.6 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 64.7% year-over-year to $16.6 million; the TTM value through Dec 2025 reached $45.8 million, up 22.79%, while the annual FY2025 figure was $45.8 million, 22.79% up from the prior year.
  • Gross Profit reached $16.6 million in Q4 2025 per PACB's latest filing, up from $15.9 million in the prior quarter.
  • Across five years, Gross Profit topped out at $17.9 million in Q3 2023 and bottomed at -$1.4 million in Q1 2025.
  • Average Gross Profit over 5 years is $12.2 million, with a median of $13.6 million recorded in 2021.
  • The widest YoY moves for Gross Profit: up 147.29% in 2025, down 112.15% in 2025.
  • A 5-year view of Gross Profit shows it stood at $16.8 million in 2021, then plummeted by 69.34% to $5.1 million in 2022, then skyrocketed by 86.21% to $9.6 million in 2023, then grew by 5.09% to $10.1 million in 2024, then surged by 64.7% to $16.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $16.6 million in Q4 2025, $15.9 million in Q3 2025, and $14.7 million in Q2 2025.